HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications.
Reversible acetylation mediated by histone deacetylases (HDACs) influences a broad repertoire of physiological processes, many of which are aberrantly controlled in tumor cells. As HDAC inhibition prompts tumor cells to enter apoptosis, small-molecule HDAC inhibitors have been developed as a new cla...
Main Authors: | Khan, O, La Thangue, N |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2012
|
Similar Items
-
Biomarkers for predicting clinical responses to HDAC inhibitors.
by: Stimson, L, et al.
Published: (2009) -
HDAC inhibitor-based therapies and haematological malignancy.
by: Stimson, L, et al.
Published: (2009) -
A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors.
by: New, M, et al.
Published: (2013) -
A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors
by: New, M, et al.
Published: (2013) -
HDAC inhibitor-based therapies: can we interpret the code?
by: New, M, et al.
Published: (2012)